Greg Cima

A decline in demand for rapid COVID-19 antigen tests dragged on the company's diagnostics division while lockdowns in China reduced routine testing.

The firm beat predictions for the quarter on the strength of its other molecular diagnostics business, and it predicts double-digit revenue growth for the year. 

The firm is developing a shoebox-size gas chromatography instrument that could be used for routine screenings and critical illness detection and monitoring.

The Cue Health-sponsored ImmunoCare study is testing the value of giving immunocompromised people at-home tests, telemedicine, and prescription delivery.

At the JP Morgan Healthcare conference, CEO Steve MacMillan especially noted Africa as an underserved market for women's health.

The lightweight, portable instruments coming onto the market employ promise to deliver test results closer to patients, potentially hastening treatments.

State labs and commercial companies see rising spinal muscular atrophy test volumes as screening programs launch in US states and European countries, among others.

The four-year National Institutes of Health-funded project is coordinating hundreds of researchers with goals of determining the causes and effects of long COVID.

The Netherlands-based firm said its Raman spectroscopy instrument can detect and differentiate bacteria in minutes and help reduce unnecessary antimicrobial use.

The firm said it will cut costs and streamline operations by consolidating its immunoassay and clinical chemistry offerings into the Atellica Solution lineup and phase out older platforms.